IGF-1 LR3 vs IGF-1 DES
IGF-1 LR3 vs IGF-1 DES — long systemic vs short local action, half-life differences, dosing logistics, and why DES is less common in practice.
Updated May 7, 2026 · 5 min read
IGF-1 LR3 and IGF-1 DES are both IGF-1 analogues, but they're built for opposite use cases. IGF-1 LR3 is engineered for long, systemic exposure — one daily injection, multi-hour half-life, body-wide IGF-1 receptor activation. IGF-1 DES is the opposite: extremely short half-life, intended for local injection at the training site to drive a tight, localized growth response. In practice the strength community uses LR3 vastly more often, and the reasons are largely logistical rather than mechanistic.
What each molecule actually is
| Property | IGF-1 LR3 | IGF-1 DES |
|---|---|---|
| Full name | Long-Arg3 IGF-1 | Des(1-3) IGF-1 |
| Modification | Arg3 substitution + 13-aa N-terminal extension | First three N-terminal amino acids removed |
| Length | 83 amino acids | 67 amino acids |
| Half-life | 20–30 hours | 20–30 minutes |
| IGFBP binding | Very low | Very low |
| Receptor potency | About 2–3x natural IGF-1 | About 5–10x natural IGF-1 at the site |
| Reach | Systemic | Effectively local at injection site |
IGF-1 DES is more potent per molecule at the IGF-1 receptor, but its half-life is so short that systemic exposure is minimal. The thinking with DES: inject directly into or next to the target muscle right around training, get an intense local pulse, then the molecule is cleared before it can drive systemic side effects.
The mechanism difference matters
IGF-1 LR3's long half-life means it floods every tissue with an IGF-1 receptor — muscle, tendon, gut, brain, anywhere the receptor lives. That's the appeal (broad anabolic signaling) and the concern (broad receptor activation includes tissues you might not want to amplify).
IGF-1 DES's short half-life means most of the molecule never makes it past the local interstitium before clearance. The intended profile is a 30-minute local saturation at the training site. The systemic IGF-1 spike is real but small.
In theory, this gives DES a sharper risk-benefit profile for local hypertrophy work. In practice, the data backing the local-only use case is thin, and most systemic IGF-1-axis concerns still apply.
Dosing differences
| Detail | IGF-1 LR3 | IGF-1 DES |
|---|---|---|
| Typical daily dose | 20–50 mcg | 50–100 mcg per training session |
| Frequency | Once or twice daily | Only on training days |
| Site | Standard SubQ rotation | Intramuscular near working muscle |
| Timing | Pre or post-workout, or split | 15–30 min pre-workout |
| Cycle length | 4–6 weeks | 4–6 weeks |
DES doses run higher per injection than LR3 because the rapid clearance limits exposure. The trade-off is that you're injecting near or into specific working muscles each training session, which is logistically more demanding.
Why DES is used less often
Several practical reasons:
- Logistical burden. DES requires injection right before each training session, into or near the working muscle. Skipped training days mean no dose. Travel or schedule changes break the protocol.
- Site-targeting questions. The "inject near the muscle for local effect" idea sounds clean, but interstitial diffusion and rapid systemic clearance mean the local-only theory is partially aspirational. Some of the dose goes systemic anyway.
- Sourcing. IGF-1 LR3 is widely synthesized. IGF-1 DES is less common, and counterfeit risk is elevated when fewer reputable vendors carry it.
- Cost per cycle. DES typically costs more per mg, and you're using larger doses per session.
- No clinical advantage demonstrated. The hypothetical benefit of "local action only" hasn't been demonstrated to outperform LR3 for hypertrophy outcomes in any controlled comparison.
For most users targeting body-comp or strength gains, LR3 covers the use case more cleanly.
When DES might fit
The narrow case for IGF-1 DES:
- Specific lagging body part work. A user with disciplined training and one body part they're isolating — chest, calves, back width — might run DES as a localized hypertrophy push.
- Lower systemic IGF-1 exposure preferred. Users who want IGF-1 receptor activation at the working muscle but are uncomfortable with multi-hour systemic IGF-1 elevation might prefer DES on principle.
- Experienced peptide users on a defined block. First-time peptide users should not start with DES — it's logistically unforgiving.
Side-effect profile compared
| Effect | IGF-1 LR3 | IGF-1 DES |
|---|---|---|
| Hypoglycemia | Common, sustained | Acute, short-lived |
| Hand numbness / carpal tunnel | Occasional | Rare |
| Headaches | Occasional | Rare |
| Joint aches | Occasional | Rare |
| Local injection-site reactions | Mild | More common (intramuscular) |
| Fatigue | Common in week one | Rare |
The DES profile is generally cleaner for sustained side effects because exposure is so brief. Acute hypoglycemia after a DES injection is real, but it resolves quickly.
The cancer-axis question for both
Both molecules activate the IGF-1 receptor, which is the variable the cancer-mechanism literature cares about. DES's short half-life produces less cumulative exposure per dose, which is a legitimate point in its favor — but neither molecule is appropriate for users with active or recent cancer, or strong family history of hormone-sensitive cancer. See cancer concerns.
The honest take
For nearly every reader of this site, IGF-1 LR3 is the right molecule if you've decided to run an IGF-1 analogue at all. It's better-supplied, easier to dose consistently, and the use case it covers (sustained anabolic signaling on a 4–6 week block) matches what most strength users actually want. DES is interesting in theory and occasionally useful in narrow cases, but it's not the default starting point.